Unfortunately, despite great progress in the treatment of lung cancer, resistance to EGFR-TKIs commonly occurs, leading to a modest response rate to first-line TKI therapy or to frequent recurrence after temporarily effective TKI treatment [3, 4]. Here, EGFR is linked to lung carcinoma.